Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 1388Neoplasms 1168Colorectal Neoplasms 626Lung Neoplasms 562Prostatic Neoplasms 538Carcinoma, Non-Small-Cell Lung 444Carcinoma, Hepatocellular 296Stomach Neoplasms 272Pancreatic Neoplasms 270Colonic Neoplasms 264Ovarian Neoplasms 231Head and Neck Neoplasms 228Rectal Neoplasms 221Melanoma 216Multiple Myeloma 204Uterine Cervical Neoplasms 198Lymphoma 195Leukemia 193Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Neoplasm Metastasis 178Carcinoma, Renal Cell 177Brain Neoplasms 174Esophageal Neoplasms 173Leukemia, Myeloid, Acute 158Urinary Bladder Neoplasms 138Recurrence 123Polycystic Ovary Syndrome 122Liver Neoplasms 119Hematologic Neoplasms 117Endometrial Neoplasms 107

Interventions

avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Observational × Urothelial Cancer × Clear all
NCT07207928 2026-01-09

AvePem

Azienda Ospedaliera Universitaria Integrata Verona

Completed
35 enrolled
Genitourinary

Urothelial Cancer

NCT05366725 2025-12-02

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Completed
106 enrolled 36 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡